GlassScriptPhysician profile
Kibibi A Wanzu
NPI 1043689623
$1,990.28
in general payments reported to CMS, 2019-2025
13 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.19 · 2020: $14.24 · 2021: $1,426 · 2022: $127 · 2023: $98.89 · 2024: $15.12 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $181 · Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $181.16 |
| Food and Beverage | $153.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,387.84 | 2021 | |
| Integra Lifesciences Corporation | $221.19 | 2019-2025 | Integra |
| Smith+Nephew, INC. | $89.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $66.45 | 2023 | Xarelto |
| Organogenesis INC. | $64.13 | 2021-2023 | Puraply |
| Averitas Pharma INC. | $39.60 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $24.74 | 2019 | |
| Hikma Pharmaceuticals USA | $17.74 | 2019 | |
| Veryan Medical Incorporated | $17.68 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.84 | 2019 | |
| Arthrosurface Incorporated | $15.75 | 2019 | |
| Nevro Corp. | $15.12 | 2024 | Senza |
| Stryker Corporation | $14.98 | 2023 | Sonicanchor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kibibi Wanzu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.